IFN-β and its derivatives are an important treatment option for relapsing remitting multiple sclerosis (MS), clinically isolated syndrome and secondary progressive MS, due to their ability to attenuate the relapse rate and slow progression of the disease [11]. The gene discussed is IFNB1; the disease is myeloid sarcoma.